BioXcel Therapeutics Inc (NASDAQ: BTAI) kicked off on Tuesday, up 6.57% from the previous trading day, before settling in for the closing price of $0.67. Over the past 52 weeks, BTAI has traded in a range of $0.50-$5.62.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 53.60% over the past five years. While this was happening, its average annual earnings per share was recorded 69.07%. With a float of $32.45 million, this company’s outstanding shares have now reached $40.74 million.
Let’s look at the performance matrix of the company that is accounted for 74 employees. In terms of profitability, gross margin is 33.37%, operating margin of -4494.88%, and the pretax margin is -4487.39%.
BioXcel Therapeutics Inc (BTAI) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of BioXcel Therapeutics Inc is 20.35%, while institutional ownership is 24.10%. The most recent insider transaction that took place on Oct 03 ’24, was worth 3,450. In this transaction Chief Commercial Officer of this company sold 6,272 shares at a rate of $0.55, taking the stock ownership to the 19,011 shares. Before that another transaction happened on Oct 03 ’24, when Company’s See Remarks sold 6,863 for $0.55, making the entire transaction worth $3,775. This insider now owns 23,770 shares in total.
BioXcel Therapeutics Inc (BTAI) Performance Highlights and Predictions
In the latest quarterly report, which was put into the public domain on 6/30/2024, the organization reported -1.72 earnings per share (EPS), lower than consensus estimate (set at -1.3) by -0.42. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.53 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 69.07% per share during the next fiscal year.
BioXcel Therapeutics Inc (NASDAQ: BTAI) Trading Performance Indicators
Take a look at BioXcel Therapeutics Inc’s (BTAI) current performance indicators. Last quarter, stock had a quick ratio of 2.25. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 12.07.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.55, a number that is poised to hit -0.51 in the next quarter and is forecasted to reach -1.41 in one year’s time.
Technical Analysis of BioXcel Therapeutics Inc (BTAI)
BioXcel Therapeutics Inc (NASDAQ: BTAI) saw its 5-day average volume 0.38 million, a negative change from its year-to-date volume of 0.85 million. As of the previous 9 days, the stock’s Stochastic %D was 87.17%. Additionally, its Average True Range was 0.05.
During the past 100 days, BioXcel Therapeutics Inc’s (BTAI) raw stochastic average was set at 19.32%, which indicates a significant decrease from 95.58% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 58.73% in the past 14 days, which was lower than the 86.26% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.5947, while its 200-day Moving Average is $1.7721. Nevertheless, the first resistance level for the watch stands at $0.7403 in the near term. At $0.7697, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.8195. If the price goes on to break the first support level at $0.6611, it is likely to go to the next support level at $0.6113. Assuming the price breaks the second support level, the third support level stands at $0.5819.
BioXcel Therapeutics Inc (NASDAQ: BTAI) Key Stats
The company with the Market Capitalisation of 28.96 million has total of 40,744K Shares Outstanding. Its annual sales at the moment are 1,380 K in contrast with the sum of -179,050 K annual income. Company’s last quarter sales were recorded 1,100 K and last quarter income was -8,300 K.
